NEW YORK - Purigen Biosystems said on Thursday that it has signed an agreement with GC Biotech for the distribution of its nucleic acid extraction system in Belgium, the Netherlands, and Luxembourg.
Under the agreement, GC Biotech obtained the exclusive rights to distribute, service, and support Purigen's Ionic Purification System and microfluidic kits in the Benelux countries.
"Purigen's Ionic Purification System and kits are a strong addition to our overall product portfolio and will enable our customers to rapidly generate higher yields of DNA or RNA from their most precious biological samples," Glenn Nohar, GC Biotech's owner and CEO, said in a statement.
Launched in the US market in 2019, the Ionic Purification System enables the automated extraction of nucleic acids from a wide range of sample types, including cultured or sorted cells and formalin-fixed, paraffin-embedded tissues, Purigen said. The small benchtop instrument received CE marking in May 2021.
"This agreement is a significant step towards our goal of making the Ionic system readily available across the entire European Union," said Aziz Mustafa, senior director of European sales and business development for Purigen, in a statement.
Earlier this year, Pleasanton, California-based Purigen inked two other distribution deals for the Ionic system in Spain, Portugal, and Eastern Europe.